What is HC Wainwright’s Estimate for KPRX FY2024 Earnings?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) – Stock analysts at HC Wainwright lowered their FY2024 earnings per share estimates for shares of Kiora Pharmaceuticals in a report released on Monday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $1.28 per share for the year, down from their previous forecast of $1.58. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $1.17 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at $0.67 EPS and FY2025 earnings at ($2.76) EPS.

Kiora Pharmaceuticals Price Performance

Shares of NASDAQ KPRX opened at $3.44 on Thursday. The business’s 50-day simple moving average is $3.53 and its 200-day simple moving average is $4.28. Kiora Pharmaceuticals has a 52 week low of $3.00 and a 52 week high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.09.

Hedge Funds Weigh In On Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for about 0.8% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th biggest position. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals at the end of the most recent quarter. 76.97% of the stock is currently owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.